Clinical Trial Update: Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial updating Apatinib in combination with EGFR-TKI for advanced EGFR-TKI-resistant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• EGFR-TKI (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Nonsmall Cell Lung Cancer | Phase 1 | Status: UNKNOWN